Naringin inhibits growth and induces apoptosis by a mechanism dependent on reduced activation of NF-κB/COX-2-caspase-1 pathway in HeLa cervical cancer cells

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 1929-1936

  Zeng, Lan ^a   Zhen, Yulan ^b   Chen, Yiming ^a   Zou, Lin ^b   Zhang, Ying ^b   Hu, Fen ^c   Feng, Jianqiang ^d   Shen, Jianhua ^a   Wei, Bing ^b  

^a Hospital of Traditional Chinese Medicine in Liwan District of Guangzhou   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c Fujian Medical College   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Caspase 1; Cell growth; Cervical cancer; Cyclooxygenase 2; Naringin; Nuclear factor B

Indexed keywords

AURANTIIN; CASPASE 3; CASPASE INHIBITOR; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA CONVERTING ENZYME; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PYRROLIDINE DITHIOCARBAMATE; SC 3069; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; FLAVANONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PTGS2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

APOPTOSIS; CASPASE 1; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2; FEMALE; FLAVANONES; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; NF-KAPPA B; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 84907202598     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2617     Document Type: Article

References (53)

1. Münger K, Baldwin A, Edwards KM, et al: Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78: 11451-11460, 2004.
2. Karin M and Greten FR: NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759, 2005.
3. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 14: 649-683, 1996.
4. Yang C, Ling H, Zhang M, et al: Oxidative stress mediates chemical hypoxia-induced injury and inflammation by activating NF-?b-COX-2 pathway in HaCaT cells. Mol Cells 31: 531-538, 2011.
5. Yang C, Yang Z, Zhang M, et al: Hydrogen sulfide protects against chemical hypoxia-induced cytotoxicity and inflammation in HaCaT cells through inhibition of ROS/NF-κB/COX-2 pathway. PLoS One 6: E21971, 2011.
6. Guo RM, Xu WM, Lin JC, et al: Activation of the p38 MAPK/NF-κB pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells. Mol Med Rep 8: 603-608, 2013.
7. Lu H, Ouyang W and Huang C: Inflammation, a key event in cancer development. Mol Cancer Res 4: 221-233, 2006.
8. Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78, 2004.
9. Kim SH, Oh JM, No JH, Bang YJ, Juhnn YS and Song YS: Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 30: 753-757, 2009.
10. Li J, Jia H, Xie L, et al: Association of constitutive nuclear factor-kappaB activation with aggressive aspects and poor prognosis in cervical cancer. Int J Gynecol Cancer 19: 1421-1426, 2009.
11. Wu Z, Peng X, Li J, Zhang Y and Hu L: Constitutive activation of nuclear factor κB contributes to cystic fibrosis transmembrane conductance regulator expression and promotes human cervical cancer progression and poor prognosis. Int J Gynecol Cancer 23: 906-915, 2013.
12. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS and Holt PR: Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117: 838-847, 1999.
13. Vane JR, Bakhle YS and Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120, 1998.
14. Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG and Ryu WS: Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 7: 1410-1418, 2001.
15. Dubois RN: Review article: Cyclooxygenase -A target for colon cancer prevention. Aliment Pharmacol Ther 14 (Suppl 1): 64-67, 2000.
16. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM and Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397-11403, 2000.
17. Grossman EM, Longo WE, Panesar N, Mazuski JE and Kaminski DL: The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells. Carcinogenesis 21: 1403-1409, 2000.
18. Khuri FR, Wu H, Lee JJ, et al: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7: 861-867, 2001.
19. Higashi Y, Kanekura T and Kanzaki T: Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: Evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 86: 667-671, 2000.
20. Kulkarni S, Rader JS, Zhang F, et al: Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7: 429-434, 2001.
21. Ferrandina G, Lauriola L, Distefano MG, et al: Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 20: 973-981, 2002.
22. Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC and Oh KS: High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 76: 320-325, 2000.
23. Gaffney DK, Holden J, Davis M, Zempolich K, Murphy KJ and Dodson M : Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 49: 1213-1217, 2001.
24. Weppelmann B and Mönkemeier D: The influence of prostaglandin antagonists on radiation therapy of carcinoma of the cervix. Gynecol Oncol 17: 196-199, 1984.
25. Wang AH, Tian XY, Yu JJ, Mi JQ, Liu H and Wang RF: Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclo-oxygenase-2 and vascular endothelial growth factor C expression. J Int Med Res 40: 56-66, 2012.
26. Kang YJ, Wingerd BA, Arakawa T and Smith WL: Cyclooxygenase-2 gene transcription in a macrophage model of inflammation. J Immunol 177: 8111-8122, 2006.
27. Liu W, Reinmuth N, Stoeltzing O, et al: Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res 63: 3632-3636, 2003.
28. Thornberry NA, Bull HG, Calaycay JR, et al: A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356: 768-774, 1992.
29. Lamkanfi M, Kalai M, Saelens X, Declercq W and Vandenabeele P: Caspase-1 activates nuclear factor of the kappa-enhancer in B cells independently of its enzymatic activity. J Biol Chem 279: 24785-24793, 2004.
30. Sarkar A, Duncan M, Hart J, Hertlein E, Guttridge DC and Wewers MD: ASC directs NF-kappaB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions. J Immunol 176: 4979-4986, 2006.
31. Zhang WH, Wang X, Narayanan M, Zhang Y, Huo C, Reed JC and Friedlander RM: Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death. Proc Natl Acad Sci USA 100: 16012-16017, 2003.
32. Feng Q, Li P, Salamanca C, Huntsman D, Leung PC and Auersperg N: Caspase-1alpha is down-regulated in human ovarian cancer cells and the overexpression of caspase-1alpha induces apoptosis. Cancer Res 65: 8591-8596, 2005.
33. Winter RN, Rhee JG and Kyprianou N: Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Anticancer Res 24: 1377-1386, 2004.
34. Schlosser S, Gansauge F, Ramadani M, Beger HG and Gansauge S: Inhibition of caspase-1 induces cell death in pancreatic carcinoma cells and potentially modulates expression levels of bcl-2 family proteins. FEBS Lett 491: 104-108, 2001.
35. Chen J, Guo R, Yan H, et al: Naringin inhibits ROS-Activated MAPK pathway in high glucose-induced injuries in H9c2 cardiac cells. Basic Clin Pharmacol Toxicol 114: 293-304, 2014.
36. Mahmoud AM, Ashour MB, Abdel-Moneim A and Ahmed OM: Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J Diabetes Complications 26: 483-490, 2012.
37. Nie YC, Wu H, Li PB, et al: Anti-inflammatory effects of naringin in chronic pulmonary neutrophilic inflammation in cigarette smoke-exposed rats. J Med Food 15: 894-900, 2012.
38. Huang H, Wu K, You Q, Huang R, Li S and Wu K: Naringin inhibits high glucose-induced cardiomyocyte apoptosis by attenuating mitochondrial dysfunction and modulating the activation of the p38 signaling pathway. Int J Mol Med 32: 396-402, 2013.
39. Chen J, Mo H, Guo R, You Q, Huang R and Wu K: Inhibition of the leptin-induced activation of the p38 MAPK pathway contributes to the protective effects of naringin against high glucose-induced injury in H9c2 cardiac cells. Int J Mol Med 33: 605-612, 2014.
40. Kaul TN, Middleton E Jr and Ogra PL: Antiviral effect of flavonoids on human viruses. J Med Virol 15: 71-79, 1985.
41. So FV, Guthrie N, Chambers AF, Moussa M and Carroll KK: Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 26: 167-181, 1996.
42. Le Marchand L, Murphy SP, Hankin JH, Wilkens LR and Kolonel LN: Intake of flavonoids and lung cancer. J Natl Cancer Inst 92: 154-160, 2000.
43. Vanamala J, Leonardi T, Patil BS, et al: Suppression of colon carcinogenesis by bioactive compounds in grapefruit. Carcinogenesis 27: 1257-1265, 2006.
44. Kim DI, Lee SJ, Lee SB, Park K, Kim WJ and Moon SK: Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression. Carcinogenesis 29: 1701-1709, 2008.
45. Schindler R and Mentlein R: Flavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells. J Nutr 136: 1477-1482, 2006.
46. Ramesh E and Alshatwi AA: Naringin induces death receptor and mitochondria-mediated apoptosis in human cervical cancer (SiHa) cells. Food Chem Toxicol 51: 97-105, 2013.
47. Choi JS and Ryter SW: Inflammasomes: Molecular Regulation and Implications for Metabolic and Cognitive Diseases. Mol Cells: May 19, 2014 (Epub ahead of print).
48. Man SM, Tourlomousis P, Hopkins L, Monie TP, Fitzgerald KA and Bryant CE: Salmonella infection induces recruitment of Caspase-8 to the inflammasome to modulate IL-1β production. J Immunol 191: 5239-5246, 2013.
49. Yusup G, Akutsu Y, Mutallip M, et al: A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. Int J Oncol 44: 1146-1152, 2014.
50. Jarry A, Vallette G, Cassagnau E, et al: Interleukin 1 and interleukin 1beta converting enzyme (caspase 1) expression in the human colonic epithelial barrier. Caspase 1 downregulation in colon cancer. Gut 45: 246-251, 1999.
51. Ueki T, Takeuchi T, Nishimatsu H, et al: Silencing of the caspase-1 gene occurs in murine and human renal cancer cells and causes solid tumor growth in vivo. Int J Cancer 91: 673-679, 2001.
52. Alnemri ES, Fernandes-Alnemri T and Litwack G: Cloning and expression of four novel isoforms of human interleukin-1 beta converting enzyme with different apoptotic activities. J Biol Chem 270: 4312-4317, 1995.
53. Chen YC, Shen SC, Chow JM, Ko CH and Tseng SW: Flavone inhibition of tumor growth via apoptosis in vitro and in vivo. Int J Oncol 25: 661-670, 2004.